Renoprotection by blocking the RAAS in diabetic nephropathy - Fact or fiction? Author's reply [1]

Nephrology Dialysis Transplantation

Volumn 21, Issue 9, 2006, Pages 2357-2358

  Suissa, Samy ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN INHIBITOR;

CLINICAL OBSERVATION; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LETTER; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW;

EID: 33750449676     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl542     Document Type: Letter

References (2)

1. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney International 2006; 69: 913-919
2. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. New Engl J Med 2001; 337: 536-542